Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

PURPOSE: Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-particle emitter (211)At-labeled to the anti-PSCA A11 minibody. A1...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EJNMMI Res
Glavni autori: Bäck, Tom A., Jennbacken, Karin, Hagberg Thulin, Malin, Lindegren, Sture, Jensen, Holger, Olafsen, Tove, Yazaki, Paul J., Palm, Stig, Albertsson, Per, Damber, Jan-Erik, Wu, Anna M., Welén, Karin
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2020
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013029/
https://ncbi.nlm.nih.gov/pubmed/32048062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-020-0600-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items